The initial public offering for LONGBIO-B (01779) concluded on June 2nd. The company offered 14.193 million H shares, with 10% allocated for the Hong Kong public offering. The offer price was set at HK$96.06 per share, aiming to raise approximately HK$1.36 billion. Each board lot consists of 50 shares, with an entry cost of HK$4,851.4 per lot. The company is expected to commence trading on June 5th, with Guojin Securities acting as the sole sponsor.

By the noon deadline on June 2nd, the public offering portion had recorded HK$462.44 billion in margin financing subscriptions. Based on the public offering size of HK$136 million, this represents an oversubscription of approximately 3,390.8 times.

According to the prospectus, LONGBIO-B is a clinical-stage biopharmaceutical company founded in 2020 and based in Shanghai and Changshu, Suzhou, China. The company primarily focuses on the independent discovery and development of biologic drugs targeting allergic and autoimmune diseases. Its pipeline includes a core product, LP-003, an anti-IgE antibody designed to block free IgE in blood and tissues to inhibit IgE-mediated allergic reactions. It is intended for treating allergic conditions such as seasonal allergic rhinitis, chronic spontaneous urticaria, allergic asthma, and other allergic diseases. The company also has a key product, LP-005, a bispecific antibody fusion protein targeting complement C5 and C3b, for treating related renal and hematological indications.

Financially, the company reported revenues of approximately RMB 3.07 million and RMB 5.586 million for the 2024 and 2025 fiscal years, respectively. For the same periods, the company's total comprehensive loss was approximately RMB 137 million and RMB 176 million, respectively.